Hostname: page-component-586b7cd67f-gb8f7 Total loading time: 0 Render date: 2024-11-25T10:14:18.433Z Has data issue: false hasContentIssue false
  • English
  • Français

Briefs from the Fields of Neurology & Psychiatry

Published online by Cambridge University Press:  07 November 2014

Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Nota Bene
Information
CNS Spectrums , Volume 2 , Issue 4: Schizophrenia & OCD: Divergence , April 1997 , pp. 14 - 55
Copyright
Copyright © Cambridge University Press 1997

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Giacobini, E.Cholinomimetic Therapy of Alzheimer's Disease: does it slow down deterioration? In: Racagni, G, Brunello, N.Langer, SZ, eds. Recent advances in the treatment of neurodegenerative disorders and cognitive dysfunction. New York: International Academy of Biomedical Drug Research. 1994;7(23):51–57.Google Scholar
2.Schneider, LS.Clinical pharmacology of aminoacridines in Alzheimer's disease. Neurology. 1993;43(supp 14):S64–S79.Google Scholar
3.Becker, RE, et al.The second generation of cholinesterase inhibitors: clinical and pharmacological effects. In: Giacobini, E, Becker, R, eds. Cholinergic basis for Alzheimer therapy. Boston: Birkhauser; 1991:263–296.Google Scholar
4.Maelicke, A, Albuquerque, E. New approach to drug therapy in Alzheimer's dementia. Drug Discov today. 1996; 1:53–59.Google Scholar
5.Mori, F, et al.Cholinesterase inhibitors increase secretion of APPs in rat brain cortex. Neuro Report. 1995;6:663–696.Google Scholar
6.Schneider, LS, Olin, J, Pawluczyk, S. A double-blind crossover pilot study of a combination with cholinesterase inhibitor in Alzheimer's disease. Am J Psychiatry. 1993;150:321–323.Google ScholarPubMed